No Cover Image

Journal article 342 views 44 downloads

High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone

Lee Butcher, Jun-Cezar Zaldua Orcid Logo, Jose A. Carnicero, Karl Hawkins Orcid Logo, Janet Whitley, Rangaswamy Mothukuri, Adrian Evans Orcid Logo, Keith Morris, Suresh Pillai, Jorge D. Erusalimsky

Respiratory Research, Volume: 23, Issue: 1

Swansea University Authors: Jun-Cezar Zaldua Orcid Logo, Karl Hawkins Orcid Logo, Adrian Evans Orcid Logo

  • Butcher et al Respiratory Research 2022.pdf

    PDF | Version of Record

    © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License

    Download (2.83MB)

Check full text

DOI (Published version): 10.1186/s12931-022-02220-5

Abstract

Blood levels of the soluble receptor for advanced glycation end-products (sRAGE) are acutely elevated during the host inflammatory response to infection and predict mortality in COVID-19. However, the prognostic performance of this biomarker in the context of treatments to reduce inflammation is unc...

Full description

Published in: Respiratory Research
ISSN: 1465-993X
Published: Springer Science and Business Media LLC 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa62071
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-12-08T13:04:22Z
last_indexed 2023-01-13T19:23:17Z
id cronfa62071
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>62071</id><entry>2022-11-28</entry><title>High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone</title><swanseaauthors><author><sid>8657447b46aaea58c1d3a36faa04e37f</sid><ORCID>0000-0003-0315-5852</ORCID><firstname>Jun-Cezar</firstname><surname>Zaldua</surname><name>Jun-Cezar Zaldua</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>77c39404a9a98c6e2283d84815cba053</sid><ORCID>0000-0003-0174-4151</ORCID><firstname>Karl</firstname><surname>Hawkins</surname><name>Karl Hawkins</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>21761f6eb805546a561c9f036e85405b</sid><ORCID>0000-0002-0814-5162</ORCID><firstname>Adrian</firstname><surname>Evans</surname><name>Adrian Evans</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-11-28</date><deptcode>BMS</deptcode><abstract>Blood levels of the soluble receptor for advanced glycation end-products (sRAGE) are acutely elevated during the host inflammatory response to infection and predict mortality in COVID-19. However, the prognostic performance of this biomarker in the context of treatments to reduce inflammation is unclear. In this study we investigated the association between sRAGE and mortality in dexamethasone-treated COVID-19 patients. We studied 89 SARS-CoV-2 positive subjects and 22 controls attending the emergency department of a University Teaching Hospital during the second wave of COVID-19 and measured sRAGE at admission. In positive individuals sRAGE increased with disease severity and correlated with the National Early Warning Score 2 (Pearson’s r = 0.56, p &lt; 0.001). Fourteen out of 72 patients treated with dexamethasone died during 28 days of follow-up. Survival rates were significantly lower in patients with high sRAGE (&gt; 3532 pg/mL) than in those with low sRAGE (p = 0.01). Higher sRAGE levels were associated with an increased risk of death after adjustment for relevant covariates. In contrast, IL-6 did not predict mortality in these patients. These results demonstrate that sRAGE remains an independent predictor of mortality among COVID-19 patients treated with dexamethasone. Determination of sRAGE could be useful for the clinical management of this patient population.</abstract><type>Journal Article</type><journal>Respiratory Research</journal><volume>23</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1465-993X</issnElectronic><keywords>Mortality, Prognostic, Biomarkers, sRAGE, IL-6, NEWS2, Dexamethasone, COVID-19, SARS-CoV-2</keywords><publishedDay>5</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-11-05</publishedDate><doi>10.1186/s12931-022-02220-5</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>This study was supported by Sêr Cymru GOV.WALES</funders><projectreference/><lastEdited>2023-09-13T15:39:14.5020345</lastEdited><Created>2022-11-28T14:57:45.2921525</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Lee</firstname><surname>Butcher</surname><order>1</order></author><author><firstname>Jun-Cezar</firstname><surname>Zaldua</surname><orcid>0000-0003-0315-5852</orcid><order>2</order></author><author><firstname>Jose A.</firstname><surname>Carnicero</surname><order>3</order></author><author><firstname>Karl</firstname><surname>Hawkins</surname><orcid>0000-0003-0174-4151</orcid><order>4</order></author><author><firstname>Janet</firstname><surname>Whitley</surname><order>5</order></author><author><firstname>Rangaswamy</firstname><surname>Mothukuri</surname><order>6</order></author><author><firstname>Adrian</firstname><surname>Evans</surname><orcid>0000-0002-0814-5162</orcid><order>7</order></author><author><firstname>Keith</firstname><surname>Morris</surname><order>8</order></author><author><firstname>Suresh</firstname><surname>Pillai</surname><order>9</order></author><author><firstname>Jorge D.</firstname><surname>Erusalimsky</surname><order>10</order></author></authors><documents><document><filename>62071__25938__be9a72e0fe72426ebcdde4a1b6c84052.pdf</filename><originalFilename>Butcher et al Respiratory Research 2022.pdf</originalFilename><uploaded>2022-11-28T14:59:25.1767136</uploaded><type>Output</type><contentLength>2968322</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 62071 2022-11-28 High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone 8657447b46aaea58c1d3a36faa04e37f 0000-0003-0315-5852 Jun-Cezar Zaldua Jun-Cezar Zaldua true false 77c39404a9a98c6e2283d84815cba053 0000-0003-0174-4151 Karl Hawkins Karl Hawkins true false 21761f6eb805546a561c9f036e85405b 0000-0002-0814-5162 Adrian Evans Adrian Evans true false 2022-11-28 BMS Blood levels of the soluble receptor for advanced glycation end-products (sRAGE) are acutely elevated during the host inflammatory response to infection and predict mortality in COVID-19. However, the prognostic performance of this biomarker in the context of treatments to reduce inflammation is unclear. In this study we investigated the association between sRAGE and mortality in dexamethasone-treated COVID-19 patients. We studied 89 SARS-CoV-2 positive subjects and 22 controls attending the emergency department of a University Teaching Hospital during the second wave of COVID-19 and measured sRAGE at admission. In positive individuals sRAGE increased with disease severity and correlated with the National Early Warning Score 2 (Pearson’s r = 0.56, p < 0.001). Fourteen out of 72 patients treated with dexamethasone died during 28 days of follow-up. Survival rates were significantly lower in patients with high sRAGE (> 3532 pg/mL) than in those with low sRAGE (p = 0.01). Higher sRAGE levels were associated with an increased risk of death after adjustment for relevant covariates. In contrast, IL-6 did not predict mortality in these patients. These results demonstrate that sRAGE remains an independent predictor of mortality among COVID-19 patients treated with dexamethasone. Determination of sRAGE could be useful for the clinical management of this patient population. Journal Article Respiratory Research 23 1 Springer Science and Business Media LLC 1465-993X Mortality, Prognostic, Biomarkers, sRAGE, IL-6, NEWS2, Dexamethasone, COVID-19, SARS-CoV-2 5 11 2022 2022-11-05 10.1186/s12931-022-02220-5 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University Another institution paid the OA fee This study was supported by Sêr Cymru GOV.WALES 2023-09-13T15:39:14.5020345 2022-11-28T14:57:45.2921525 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Lee Butcher 1 Jun-Cezar Zaldua 0000-0003-0315-5852 2 Jose A. Carnicero 3 Karl Hawkins 0000-0003-0174-4151 4 Janet Whitley 5 Rangaswamy Mothukuri 6 Adrian Evans 0000-0002-0814-5162 7 Keith Morris 8 Suresh Pillai 9 Jorge D. Erusalimsky 10 62071__25938__be9a72e0fe72426ebcdde4a1b6c84052.pdf Butcher et al Respiratory Research 2022.pdf 2022-11-28T14:59:25.1767136 Output 2968322 application/pdf Version of Record true © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License true eng http://creativecommons.org/licenses/by/4.0/
title High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
spellingShingle High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
Jun-Cezar Zaldua
Karl Hawkins
Adrian Evans
title_short High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
title_full High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
title_fullStr High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
title_full_unstemmed High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
title_sort High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone
author_id_str_mv 8657447b46aaea58c1d3a36faa04e37f
77c39404a9a98c6e2283d84815cba053
21761f6eb805546a561c9f036e85405b
author_id_fullname_str_mv 8657447b46aaea58c1d3a36faa04e37f_***_Jun-Cezar Zaldua
77c39404a9a98c6e2283d84815cba053_***_Karl Hawkins
21761f6eb805546a561c9f036e85405b_***_Adrian Evans
author Jun-Cezar Zaldua
Karl Hawkins
Adrian Evans
author2 Lee Butcher
Jun-Cezar Zaldua
Jose A. Carnicero
Karl Hawkins
Janet Whitley
Rangaswamy Mothukuri
Adrian Evans
Keith Morris
Suresh Pillai
Jorge D. Erusalimsky
format Journal article
container_title Respiratory Research
container_volume 23
container_issue 1
publishDate 2022
institution Swansea University
issn 1465-993X
doi_str_mv 10.1186/s12931-022-02220-5
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Blood levels of the soluble receptor for advanced glycation end-products (sRAGE) are acutely elevated during the host inflammatory response to infection and predict mortality in COVID-19. However, the prognostic performance of this biomarker in the context of treatments to reduce inflammation is unclear. In this study we investigated the association between sRAGE and mortality in dexamethasone-treated COVID-19 patients. We studied 89 SARS-CoV-2 positive subjects and 22 controls attending the emergency department of a University Teaching Hospital during the second wave of COVID-19 and measured sRAGE at admission. In positive individuals sRAGE increased with disease severity and correlated with the National Early Warning Score 2 (Pearson’s r = 0.56, p < 0.001). Fourteen out of 72 patients treated with dexamethasone died during 28 days of follow-up. Survival rates were significantly lower in patients with high sRAGE (> 3532 pg/mL) than in those with low sRAGE (p = 0.01). Higher sRAGE levels were associated with an increased risk of death after adjustment for relevant covariates. In contrast, IL-6 did not predict mortality in these patients. These results demonstrate that sRAGE remains an independent predictor of mortality among COVID-19 patients treated with dexamethasone. Determination of sRAGE could be useful for the clinical management of this patient population.
published_date 2022-11-05T15:39:16Z
_version_ 1776933621214478336
score 11.013148

Similar Items